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Abstract
We have previously demonstrated that brief treatment of APP transgenic mice with metal ionophores (PBT2, Prana
Biotechnology) rapidly and markedly improves learning and memory. To understand the potential mechanisms of action
underlying this phenomenon we examined hippocampal dendritic spine density, and the levels of key proteins involved in
learning and memory, in young (4 months) and old (14 months) female Tg2576 mice following brief (11 days) oral treatment
with PBT2 (30 mg/kg/d). Transgenic mice exhibited deficits in spine density compared to littermate controls that were
significantly rescued by PBT2 treatment in both the young (+17%, p,0.001) and old (+32%, p,0.001) animals. There was no
effect of PBT2 on spine density in the control animals. In the transgenic animals, PBT2 treatment also resulted in significant
increases in brain levels of CamKII (+57%, p=0.005), spinophilin (+37%, p=0.04), NMDAR1A (+126%, p=0.02), NMDAR2A
(+70%, p=0.05), pro-BDNF (+19%, p=0.02) and BDNF (+19%, p=0.04). While PBT2-treatment did not significantly alter
neurite-length in vivo, it did increase neurite outgrowth (+200%, p=0.006) in cultured cells, and this was abolished by co-
incubation with the transition metal chelator, diamsar. These data suggest that PBT2 may affect multiple aspects of snaptic
health/efficacy. In Alzheimer’s disease therefore, PBT2 may restore the uptake of physiological metal ions trapped within
extracellular b-amyloid aggregates that then induce biochemical and anatomical changes to improve cognitive function.
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Introduction
Alzheimer’s disease (AD) is characterized by deficits in higher
order cognitive processes. One of the principal substrates for this
dysfunction isspine/synaptic loss, which studies inAD animal models
have demonstrated is most pronounced in the immediate vicinity of
Ab plaques [1,2,3]. Furthermore, Ab oligomers impair NMDAR-
dependent signalling cascades, ultimately resulting in the progressive
loss of dendritic spines and glutamatergic synapses [4,5,6].
One of the mechanisms likely to mediate such deleterious
effects is perturbed trafficking of essential synaptic metal ions,
such as zinc. Synaptic Zn
2+ functions as a neuronal messenger
and a modulator of synaptic transmission and plasticity through
targeted interactions with proteins such as TrkB and NMDAR2b
[7,8]. The attraction of Ab oligomers to Zn
2+ emanating from the
glutamatergic synapse selectively occludes the NMDAR2b
subunit [9]. Thus, the sequestration of Zn
2+ in oligomeric Ab-
Zn complexes may lead to a reduction in zinc turnover at the
synapse, limiting the trans-synaptic movement of zinc to
modulate post-synaptic targets, and resulting in impaired
cognition.
Drug candidates clioquinol (CQ) and PBT2 (Prana Biotech-
nology Ltd) have a moderate affinity for metal ions, and rather
than deplete biological metals in cell culture, promote the uptake
of Cu and Zn [10]. We have previously demonstrated [10] that
brief administration of CQ and PBT2 (11 days, 30 mg/kg) to
both Tg2576 and APP/PS1 transgenic mice resulted in decreased
brain Ab burden with rapid (within 5 days) and marked
improvements in learning and memory performance on the
Morris water maze. PBT2 also induced cognitive benefits in a
phase IIa clinical trial [11,12]. To understand the mechanisms
that underlie this restoration of cognition, we studied the effect of
PBT2 on synaptic plasticity-related endpoints in both cell culture
and Tg2576 mice.
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All animal procedures were approved by the Howard Florey
Institute animal ethics committee (Melbourne, Australia), and
were carried out in accordance with the Australian code of
practice for the care and use of animals for scientific purposes as
described by the National Health and Medcial Research Council
of Australia. Female Tg2576 animals were group-housed and aged
to 4 or 14 months. For 11 days prior to culling, animals were given
a daily oral gavage of sham (standard suspension vehicle [10]) or
PBT2 (30 mg/kg, provided by Prana Biotechnology Ltd, Mel-
bourne, Australia) in the same vehicle (n=8–12 mice/group total;
split between golgi and biochemical analyses). One hour following
the last drug dose, animals were culled and the brain either
immediately processed for Golgi analysis, or frozen at 280uC for
subsequent biochemical analyses. The dose of PBT2 was chosen
based upon our own historical data, where we have shown that
this level of exposure to the compound effectively modulates a
number of biochemical and behavioural parameters in various
transgenic mouse models of AD, but does not alter bulk brain
metal levels [10]. With regards to how this relates to a human
dose, based upon FDA guidelines a dose of 30 mg/kg in a mouse
equates to a dose of 183 mg/day in a 75 kg man. Our published
human clinical trial data demonstrated that PBT2 was found to be
therapeutic at 250 mg/day [11,12].
Golgi staining
A subset of animals (n=3–5 mice/group) were deeply
anaesthetized with sodium pentobarbitone (100 mg/kg) and then
transcardially perfused with 0.01 M cold PBS. Brains were then
rapidly removed and cut into 4 mm blocks. The blocks containing
the hippocampus were incubated in rapid golgi solutions (Rapid
Golgi Stain Kit, MTR scientific), based on the methods of Glasser
and Van der Loos [13]. The blocks were infused with a solution
containing potassium dichromate, potassium chromate and
mercuric chloride for two weeks. The blocks were then snap
frozen and cut at 90 mm using a microtome (Cryostat, Leica
CM18-50, Leica Microsystems, Nussloch GmbH, Germany).
Sections were collected at the level of the hippocampus (bregma
21.40 to 22.70) and thaw-mounted onto gelatinized microscope
slides. The slides were dried, dehydrated, cleared with xylene and
mounted with distyrene plasticized xylene (DPX). Golgi-treated
brain tissue was analysed with a light microscope with an oil
immersion lens (63x, NA 1.3; Leica DM4000B, Leica Micro-
systems; with a further magnification from the projection lens to
the camera (10x) used for all measurements, providing a total
magnification of 630 times). The whole neuron was traced
manually.
Five neurons from each animal (n=3–5 animals/group) were
randomly selected for hippocampal spine analysis. Neurons were
selected only if; they were clearly identified as being from the CA1
subfield, the neurons appeared completely filled and they were far
enough from the neighbouring Golgi stained cells to be
individually identified. Tertiary or greater order apical and basal
dendrites (n=5 apical and n=5 basal) were selected and analysed
to determine spine density, dendritic length and dendritic number
(a cartoon outlining this method is shown in Figure S1). Thus, 50
dendrites were sampled from each animal. The standard
deviations indicate the uniformity of the analyses and demonstrate
that this is a representative sampling.
Biochemical analyses
Western blot, as previously described [14], was used for the
quantitation of protein levels in individual hippocampi taken from
a subset of animals (n=5–7 mice/group). The antibodies utilized
are outlined in Table S1.
Cell culture
Diaminosarcophagine (1,8-diamino-3,6,10,13,16,19 hexaazabi-
cyclo[6.6.6]icosane), abbreviated to (NH2)2sar and given the trivial
name ‘‘diamsar’’, was synthesised as previously reported [15].
For biochemical studies, SH-SY5Y cells were utilised (in
DMEM+10% serum), cells harvested after one hour exposure to
the various treatments and then western blots performed (n=6
replicates for each treatment).
Neurite outgrowth studies, which were conducted separately
from the biochemical studies, utilised PC12 cells (grown in
DMEM+10% fetal bovine serum) treated with NGF at 50 ng/ml
in serum-free DMEM for 48 h. DMSO vehicle, 150 nM PBT2,
150 nM CuCl2, 150 nM ZnCl2, 150 nM PBT2-Zn (equimolar
PBT2 and ZnCl2), 5 mM diamsar, 150 nM PBT2 plus 5 mM
diamsar or 150 nM PBT2-Zn plus 5 mM diamsar were then added
for 24 h. Treated cells were photographed and Image J software
(NIH) used to determine the proportion of cells that had neurites
2x or longer than the width of the cell body, and to obtain a mean
neurite length (n$6 images from 3 cultures for each treatment).
Statistics
All analyses were performed by an operator that was blinded to
the experimental conditions. An ANOVA followed by a post-hoc
Tukey’s multiple comparison test was performed for all compar-
isons (GraphPad Prism Version 5.0b).
Results
Initial assessment of 4 month old wildtype animals did not
reveal any significant effect of PBT2 on dendritic spine density
(apical =27.5% and basal =21.8%; both compared to sham-
treated wildtypes), suggesting that there was no generic effect of
PBT2 on this endpoint. This is consistent with our previous report,
where there was no effect of PBT2 on the performance of wildtype
animals in the Morris water maze [10].
PBT2 increases hippocampal apical spine density in
Tg2576 mice
Consistent with previous reports [16,17], we demonstrated that
Tg2576 mice have decreased apical spine density compared to
age-matched WTs (sample image in Figure S2). These deficits
occurred as early as 4 months of age (213%, p,0.01) and were
more severe at 14 months of age (231%, p,0.001) (Figure 1A).
Treatment of young Tg2576 mice with PBT2 for 11 days
resulted in an increase in apical spine density (+17%, p,0.001)
that abolished the deficits seen in younger sham-treated Tg
animals (Figure 1A). In older animals, PBT2-treatment also
resulted in an increase in apical spine density (+32%, p,0.001),
which approached WT levels (Figure 1A).
There was also an age-related decrease in apical spine density
evident only in both Tg groups (sham-treated, 224%, p=0.001;
PBT2-treated, 215%, p,0.0001) (Figure 1A).
PBT2 increases basal spine density in Tg2576 mice
There were no genotype-specific changes in basal spine density
at either age (Figure 1B). There was, however, an age-related
deficit in basal spine density observed in WT (215%, p=0.0017)
and a similar trend in the sham-treated Tg mice. In contrast, 14
month old Tg2576 mice treated with PBT2 had greater basal
spine density (+26%, p,0.001) than sham-treated controls, with
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(Figure 1B).
There were no significant changes in dendritic number or
length observed in 14 month old animals treated with PBT2
(Figure 1C and 1D).
PBT2 restores biochemical substrates of learning/
memory in Tg2576 mice
To explore biochemical mechanisms underlying these effects,
we assessed the levels of various proteins involved in plasticity
(Figure 2A; sample blots shown in Figure S3). Both BDNF and its
precursor, pro-BDNF, were increased (+19%, p=0.04; +19%,
p=0.02, respectively) in PBT2-treated compared to sham-treated
Tg2576 mice. The high-affinity receptor for BDNF, TrkB, showed
a trend to elevation in PBT2-treated Tg2576 mice (+91%,
p=0.06). In addition, CamKII was elevated (+57%, p=0.005)
following PBT2 treatment.
PBT2 treatment of Tg2576 mice also increased levels of
NMDAR1A and NMDAR2A (+126%, p=0.02; +70%, p=0.05
respectively), with a trend to an elevation in NMDAR2B
(+105%, p=0.06). As one of the most significantly upregulated
proteins we also sought to test the metal-dependence of this
effect in vitro. PBT2 treatment resulted in an increase in
NMDAR1A protein levels (+29%, p=0.02) that was abolished
by diamsar (249%, p,0.0001). Diamsar also reduced
NMDAR1A protein levels below that found in controls
(234%, p=0.002) (Figure 2B).
Other proteins examined in the in vivo tissues, including
AMPAr, SNAP25, synaptotagmin and PSD95 were not signifi-
cantly altered, although Creb trended towards an increase
following PBT2-treatment (Figure S4).
PBT2 increases neuritogenesis in a metal-dependent
manner in vitro
Although there was no significant effect of PBT2 on dendritic
length in vivo, our own qualitative in vitro observations (data not
shown) suggested that PBT2 was altering the appearance of cells
grown in culture. As it is possible that the treatment period used in our
in vivo studies was not sufficient to evince this morphological change,
or that there was not sufficiently high local concentrations of drug to
s e ea ne f f e c t ,w es o u g h tt oe x a m i n et h et r o p h i ce f f e c t so fP B T 2i nv i t r o
and to assess the reliance of any effects on the entry of metals into cells.
PBT2treatment resulted ina robustincreaseinneurite outgrowth
(+200%, p=0.006) (Figure 3A), which we hypothesized was due to
complexing with Zn or Cu in the buffer and then increasing cellular
metal content via its ionophore activity. Indeed, neurite outgrowth
was enhanced when PBT2 was complexed with either Cu or Zn
(+300%, p,0.0003) (Figure 3A). Cu and Zn alone, however, did not
significantly increase neurite outgrowth (Figure 3A).
Furthermore, PBT2-induced neuritogenesis required cellular
metal influx, since it was abolished by co-administration of the
high affinity metal chelator, diamsar (Figure 3B–3E). MTT assay
demonstrated that none of the treatments impaired viability
(+55%, p=0.04) (Figure S5).
Figure 1. Dendritic spine analysis in Tg2576 mice and wildtype littermates. (A) Tg2576 animals have deficits in apical dendritic spine
density at both four (n=4) and fourteen (n=5) months of age, as compared to WT mice (n=4 at four months; n=5 at fourteen months), that are
reversed by short-term (11 days) PBT2-treatment (n=3 at both age points). There are also age-related decreases in apical spine density in both the Tg
groups. (B) There is a significant increase in basal spine density in fourteen month old Tg animals treated with PBT2. There is also an age-related
decrease in basal spine density in WT animals. (C) There were no significant differences in apical or basal dendrite number across the experiment. (D)
There were no significant differences in apical or basal dendrite length across the experiment. Values are mean 6 SEM. **p,0.01, ***p,0.001.
doi:10.1371/journal.pone.0017669.g001
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We have demonstrated that brief administration of PBT2 in a tran-
sgenic mouse model of AD rectifies deficits in key biochemical memory
substrates, which may explain the rapid improvement in cognition seen
in these animals during treatment. We also demonstrated that these
effects could be mediated by metal ion uptake, consistent with the
hypothesized mechanism of action for this class of compound [10].
We have recently demonstrated that the short-term administra-
tion of the ionophores CQ and PBT2 to both APP/PS1 and
Tg2576 mice significantly reduced Ab burden and the hyper-
phosphorylation of tau [10]. These changes in classical AD
biomarkers were accompanied by a concomitant increase in
synaptophysin, a surrogate marker for synapses, and a striking
restoration of performance on the Morris water maze. The
behavioural effects were evident after less than a week of treatment,
and over the course of the study the ionophore-treated Tg animals
performed as well as or better than wildtype control mice. These
benefits were likely to be mediated by biochemical and synaptic
benefits that may result from both a reduction in Ab burden and the
mobilization of Zn and Cu trapped in Ab aggregates.
Consistent with previous reports [16,17], and actual AD
[18,19,20], we found that Tg2576 mice have deficits in dendritic
spine density (Figure 1). This was observed at 4 months of age and
was more pronounced by 14 months of age. PBT2 treatment
resulted in a near-complete restoration of apical spine density in
both young and old Tg animals, in addition to reversing the age-
related decrease in basal spine density in the Tg animals (Figure 1).
Such anatomical changes must be supported by local protein
synthesis. We therefore analysed levels of key proteins involved in
Figure 2. Biochemical profiles in Tg2576 and wildtype littermate mice and in cell culture. (A) Tg2576 mice have significant deficits in a
number of proteins, as compared to age-matched wildtype controls, and PBT2-treatment significantly increases the expression of a number of these
proteins to the levels seen in the control mice. Values have been normalized to the mean of Tg Sham group=100. (B) The effect of PBT2 on NMDAR1
protein levels in SH-SY5Y cells is abolished in the presence of the high affinity chelator, diamsar (n=6/treatment). *p,0.05, **p,0.01, #p=0.06.
doi:10.1371/journal.pone.0017669.g002
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(0.15 mM) were assessed. (A) PBT2 induces an increase in neurite outgrowth in PC12 cells that is exaggerated when PBT2 is complexed to either
copper or zinc (n=6/treatment). (B) The neuritogenic effect of PBT2 is abolished in the presence of the high affinity chelator, diamsar (n=9/
treatment). Neurite outgrowth in PC12 cells, under control (C), PBT2 (D) and PBT + diamsar (E) conditions is shown in the bottom micrographs (scale
bar =200 mm). Values are mean 6 SEM. **p,0.01, ***p,0.001.
doi:10.1371/journal.pone.0017669.g003
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events. The most prominent effects of PBT2 treatment were on
NMDA receptors (NMDAR1, 2A, 2B), which were increased
,100% above levels in sham-treated Tg mice (Figure 2). This is
consistent with the increase we observed in spine density (Figure 1),
which express glutamate receptors (such as NMDAr), whose
activation promote spine stability [21,22,23]. The downstream
signalling events from these glutamate receptors are mediated by a
variety of proteins, including CaMKII, which similarly showed a
.50% increase following PBT2 treatment (Figure 2). Signalling
proteins such as CaMKII, which is upregulated within the post-
synaptic density following neuronal activity, modulate glutamate
receptor levels and spine morphology [24,25,26]. Indeed, the
induction of LTP results in an enlargement and proliferation of
spines in a NMDAr and CaMKII-dependent manner
[27,28,29,30,31,32]. Additionally, spine survival is promoted by
elementsof the BDNF pathway [33]. BDNF,pro-BDNF,and TrkB,
were all elevated following PBT2 treatment (Figure 2), consistent
with a neurotrophic response.
Thus, PBT2 treatment results in a significant upregulation of
key proteins that is likely to result in a more active synapse,
increased structural plasticity and enhanced cognitive function. In
Tg2576 mice, where many of these pathways are deficient in
comparison to WT mice, this may explain the ability of PBT2 to
rapidly restore cognitive function.
Our observation that the effects of PBT2 are dependent upon
increasing metal uptake is consistent with our recent findings that
the expression of several of these proteins are dependent on
synaptic zinc content [14]. Aged ZnT3 KO animals, which have a
specific absence of synaptic zinc, show significant deficits in
proteins such as BDNF, pro-BDNF, TrkB and NMDA receptors.
In AD, extracellular amyloid traps Zn
2+ and Cu
2+ [34] and may
deprive the synapse of these trophic metal ions. Thus, the efficacy
of PBT2 in modulating synaptic plasticity, by reversing extracel-
lular metallostasis, may serve as one of its primary mechanisms of
action underlying the improved cognition that results following
treatment in both mice [10] and humans [11,12].
Supporting Information
Figure S1 Cartoon showing the quantitation of golgi
data. A schematic of the hippocampus, showing the different sub-
regions (CA1-3 and dentate gyrus (DG)), is shown in (A). A
representative golgi-stained image is then shown in (B), with the
traced neuron shown in (C). Also shown in panel (C) is the
orientation of the dendrites (basal/apical), together with the cell
body (CB) and the branching of the dendrites into the primary (1),
secondary (2) and tertiary (3) dendrites. The blue boxes represent
the tertiary dendrites from which spine counts were made. Panel
(D) shows a representative dendrite with spines (arrow).
(TIF)
Figure S2 Examples of golgi data. The left hand panel
shows both apical and basal dendrites. The three central figures
show typical line-drawings for dendrites from each of the three
treatments, where there is no significant change in dendrite length
or density. The images on the right hand side show images used
for calculating spine density. The Tg animals clearly have a
decreased number of spines per neurite, as compared to WT mice,
and this is normalised by PBT2 treatment.
(TIF)
Figure S3 Representative western blots. (A) shows the
various antibodies used in Figure 2A in the main text, while (B)
shows a representative blot for the data presented in Figure 2B in
the main text. All blots were normalised to GAPDH as a loading
control. WT=wildtype; Cont=control.
(TIF)
Figure S4 Biochemical profile of proteins that were not
significantly altered with PBT2 treatment.
(TIF)
Figure S5 MTT assay on SH-SY5Y cells treated with
PBT2 ± diamsar. PBT2-Zn treatment results in a significant
increase in cell viability. Values are normalised to control=100%
and are means 6 SEM *p,0.05.
(TIF)
Table S1 The various antibodies used for western blot.
(TIF)
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